GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Additional Paid-In Capital

Tourmaline Bio (Tourmaline Bio) Additional Paid-In Capital : $429.75 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Additional Paid-In Capital?


Tourmaline Bio's quarterly additional paid-in capital declined from Sep. 2023 ($351.98 Mil) to Dec. 2023 ($267.02 Mil) but then increased from Dec. 2023 ($267.02 Mil) to Mar. 2024 ($429.75 Mil).

Tourmaline Bio's annual additional paid-in capital increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.20 Mil) and increased from Dec. 2022 ($0.20 Mil) to Dec. 2023 ($267.02 Mil).

Tourmaline Bio Additional Paid-In Capital Historical Data

The historical data trend for Tourmaline Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Additional Paid-In Capital Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
- 0.20 267.02

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only - 1.03 351.98 267.02 429.75

Tourmaline Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Tourmaline Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Additional Paid-In Capital
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.